Pulmonology Medical News about Carcinoma, Non-Small-Cell Lung

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Phase I study of TLR9 agonist PF-3512676 in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer
Cancer Science, 10/23/09

Yamada K et al. – This phase I, open–label study investigated the Toll–like receptor 9 agonist, PF–3512676, in combination with carboplatin and paclitaxel in Japanese patients with advanced, non–small–cell lung cancer (NSCLC). PF–3512676 as monotherapy and in combination with chemotherapy had an acceptable safety profile in Japanese patients with treatment–naive NSCLC.

<< Previous
Solitary Fibrous Tumors of the Pleura: An Analysis of 110...

Next >>
Cystic fibrosis neutrophils have normal intrinsic reactive oxygen...

Treatment after the Failure of Gefitinib in Patients with Advanced or Recurrent Non-small Cell Lung Cancer
Anticancer Research, 11/13/09 Relevance Score: 80%

Phase II Study of Preoperative Gefitinib in Clinical Stage I Non-Small-Cell Lung Cancer
Journal of Clinical Oncology, 11/09/09 Relevance Score: 80%

Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib
Medical Oncology, 11/05/09 Relevance Score: 80%

hsa-miR-125a-5p Enhances Invasion in Non-small Cell Lung Carcinoma Cell Lines by Upregulating Rock-1
Chinese Journal of Lung Cancer, 10/20/09 Relevance Score: 80%

An Embryonic Stem Cell–Like Signature Identifies Poorly Differentiated Lung Adenocarcinoma but not Squamous Cell Carcinoma
Clinical Cancer Research, 10/12/09 Relevance Score: 80%